Trial reportDrug design, development and therapy2016
Clinical pharmacology study of cariprazine (MP-214) in patients with schizophrenia (12-week treatment).
Trial report in Drug design, development and therapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 6 syntheses or guidelines pooled it.
- Effect of dopamine partial agonist antipsychotics on suicide risk in persons with schizophrenia and schizoaffective disorders: A systematic review and meta-analysis.Schizophrenia research · 2026Pooled it
- Strategies for Switching between Oral Postsynaptic Antidopaminergic Antipsychotics in Patients with Schizophrenia: A Systematic Review.CNS drugs · 2025Pooled it
- Cariprazine and clozapine: a systematic review of a promising antipsychotic combination for treatment-resistant schizophrenia.The international journal of neuropsychopharmacology · 2025Pooled it
- Adverse effects of antipsychotics on sleep in patients with schizophrenia. Systematic review and meta-analysis.Frontiers in psychiatry · 2023Pooled it
- Real-Life Clinical Experience With Cariprazine: A Systematic Review of Case Studies.Frontiers in psychiatry · 2022Pooled it
- New Antipsychotic Medications in the Last Decade.Current psychiatry reports · 2021Pooled it
- Effect of Cariprazine on Anhedonia in Patients with Bipolar I Depression: Post Hoc Analysis of Three Randomized Placebo-Controlled Clinical Trials.Advances in therapy · 2025Trial
- Extrapolating Efficacy of Cariprazine to Pediatric Schizophrenia and Bipolar Mania Through Population Pharmacokinetic Analysis.Journal of clinical pharmacology · 2026Article
- Physiologically-Based Pharmacokinetic Model-Informed Labeling for Cariprazine Drug Interactions With CYP3A Inhibitors.CPT: pharmacometrics & systems pharmacology · 2026Article
- Effects of cariprazine on cholesterol, glucose, and weight in patients with schizophrenia: a systematic review and meta-analysis.Therapeutic advances in psychopharmacology · 2026Article
- Rational antipsychotic polypharmacy in psychotic and bipolar disorders: A focus on D2 receptor partial agonists.The mental health clinician · 2025Article
- Lack of Clinically Meaningful Effect of Cariprazine on the Pharmacokinetics of a Combined Oral Contraceptive.Neurology and therapy · 2025Article
- Clinical challenges in the dosing and titration of cariprazine.Frontiers in psychiatry · 2024Article
- Drug-Drug Interactions Between COVID-19 Treatments and Psychotropic Medications: An Updated Study.Cureus · 2023Review
- The improvement of motor symptoms in Huntington's disease during cariprazine treatment.Orphanet journal of rare diseases · 2023Article
- The antipsychotic medications aripiprazole, brexpiprazole and cariprazine are off-target respiratory chain complex I inhibitors.Biology direct · 2023Article
- Successful high dose antipsychotic treatment with cariprazine in patients on the schizophrenia spectrum: Real-world evidence from a Spanish hospital setting.Frontiers in psychiatry · 2023Article
- Successful switching from risperidone to cariprazine in a schizophrenic patient with pronounced functional deficit. Case report.Frontiers in psychiatry · 2023Article
- Add-on Cariprazine in Patients with Long-term Clozapine Treatment and Treatment Resistant Schizophrenia: Two Cases of Psychotic Deterioration and Pisa Syndrome.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2022Article
- Clozapine augmentation with cariprazine for negative symptoms: a case series and literature review.Therapeutic advances in psychopharmacology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeCariprazine is a potent dopamine D3-preferring D3/D2 receptor partial agonist in development for the treatment of schizophrenia, bipolar mania, and depression. Pharmacokinetics of cariprazine and the two clinically relevant metabolites (desmethyl- and didesmethyl-cariprazine) was evaluated in a clinical pharmacology study.
methodsThis was a multicenter, randomized, open-label, parallel-group, fixed-dose (3, 6, or 9 mg/day) study of 28-week duration (≤4-week observation, 12-week open-label treatment, and 12-week follow-up). Once-daily cariprazine was administered to 38 adult patients with schizophrenia. The pharmacokinetics of cariprazine, metabolites, and total active moieties (sum of cariprazine and two metabolites) was evaluated; efficacy and safety were also assessed.
resultsSteady state was reached within 1-2 weeks for cariprazine and desmethyl-cariprazine, 4 weeks for didesmethyl-cariprazine, and 3 weeks for total active moieties. Cariprazine and desmethyl-cariprazine levels decreased >90% within 1 week after the last dose, didesmethyl-cariprazine decreased ~50% at 1 week, and total active moieties decreased ~90% within 4 weeks. Terminal half-lives of cariprazine, desmethyl-cariprazine, and didesmethyl-cariprazine ranged from 31.6 to 68.4, 29.7 to 37.5, and 314 to 446 hours, respectively. Effective half-life (calculated from time to steady state) of total active moieties was ~1 week. Incidence of treatment-emergent adverse events was 97.4%; 15.8% of patients discontinued due to adverse events. No abnormal laboratory values or major differences from baseline in extrapyramidal symptoms were observed.
conclusionCariprazine and its active metabolites reached steady state within 4 weeks, and exposure was dose proportional over the range of 3-9 mg/day. Once-daily cariprazine was generally well tolerated in adult patients with schizophrenia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.